StemCell Therapy

In a desperate attempt to avoid the coronavirus or to make existing infections worse, arthritic patients are looking for alternative treatments for their ailment. Some even consider bizarre ones, such as the industrial lubricant, WD-40, in place of ibuprofen.

Many now fear the effects of the over-the-counter drug after previous speculations by scientists that it could make coronavirus symptoms worse. Ibuprofen has long been the drug of choice of arthritis, which many rely on to be able to walk without going through excruciating pain.

Sid Dajani, a pharmacist in Hampshire and former treasurer of the Royal Pharmaceutical Society, said that mixed messages about ibuprofen have caused people to avoid the drug altogether. According to Daily Mail, some have resorted to alternatives that seem rather odd, such as snake oils, aloe vera, and even the industrial degreaser, WD-40.

He adds that despite the NHS' latest advisory stating the drug is safe to take, sales remain to be at around a third of their normal levels.

Read Also: COVID-19: Arthritis Drug Saves 72-year-old Critically Ill Patient with Grim Condition

Worries about the drug started on March 14, when Olivier Veran, the French health minister said ibuprofen could aggravate coronavirus infections.

His comments are thought to be partly planted by remarks coming from an infectious diseases doctor. He mentioned about four young COVID-19 patients with no underlying health conditions developing severe symptoms after taking ibuprofen. A letter that had been published in the journal Lancet Respiratory Medicine three days earlier might have also caused him to believe this.

On March 16, the authors released a clarification statement saying they had merely been proposing a 'suspicion'. The following day, however, the NHS advised people with COVID-19 symptoms to avoid taking ibuprofen and instead use paracetamol.

Advice shifted again in April after the Commission on Human Medicines concluded that there is insufficient evidence that ibuprofen makes people more likely to catch COVID-19 or worsen its symptoms.

It has been reported that some were even using WD-40 on their joints, thinking that it will ease stiff joints the same way it loosens stubborn locks. Others tried using aloe vera while some went searching online for other adventurous remedies such as snake oil lotions and potions.

Dajani described how upsetting it is to see patients in pain turn to unproven or dangerous remedies when ibuprofen could help them. He describes the event as a tragedy that should not be happening.

Dr. Taher Mahmud, a consultant rheumatologist from the London Osteoporosis Clinic, said that it was 'very sad and concerning' that patients are utilizing faulty home remedies such as WD-40.

Experts believe that there is a distinct concern when it comes to pre-print and early drafts of medical and scientific papers that have not been peer-reviewed. These kinds of studies are particularly being given undue weight during the pandemic, being an easy target for criticisms and early speculations.

Also Read: Claims Ibuprofen Worsen COVID-19 are Baseless, According to EU

Original post:
Arthritis Patients Resort to Using Industrial Lubricant Over Fears Ibuprofen Might Worsen Coronavirus - Science Times

Ampersand Health has won a grant from Innovate UK to develop digital therapy solutions for people with rheumatoid arthritis.

The company was selected from over 8600 applications to receive funding by the UK government to develop digital self-management solutions for shielding RA patients.

Companies are set to benefit from a 40 million investment to drive forward new technological advances, particularly as a response to the COVID-19 outbreak.

Ampersand Health uses behavioural and data science to personalise pathways and support better self-care for people with long term inflammatory conditions. Its apps are designed to improve patients mental health and quality of life by helping address their stress management, medicine adherence, sleep quality, relationships and more; with courses for food choices and flare management in development.

The companys intervention for Crohns and Colitis patients was selected by NHSX and DHSC to be part of Techforce 19. As part of the programme, Ampersand showed that people who took its courses for a week experienced improvements in disease related quality of life and reductions in anxiety and depression.

The Innovate UK funding will allow the company and its partners - including the National Rheumatoid Arthritis Society - to invest in and evidence similar new behavioural medicines for people living with inflammatory arthritis.

A version of the platform is available for free - for the NHS via G-Cloud 11 and for patients via the app store.

Continue reading here:
Innovate UK grant to help develop digital solutions for rheumatoid arthritis - Med-Tech Innovation

The Rheumatoid Arthritis Treatment market report is an in-depth analysis of this business space. The major trends that defines the Rheumatoid Arthritis Treatment market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Latest Growth Report on Rheumatoid Arthritis Treatment Market size | Industry Segment by Applications (Hospital,Retail Pharmacies andDrugstores), by Type (Non-Steroidal Anti-inflammatory Drugs (NSAIDs),Corticosteroids andDisease-modifying anti-rheumatic drugs (DMARDs), Regional Outlook, Market Demand, Latest Trends, Rheumatoid Arthritis Treatment Growth Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2027. Analyzes current market size and upcoming seven years growth of this industry.

Other information included in the Rheumatoid Arthritis Treatment market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/195609

Revealing a gist of the competitive landscape of Rheumatoid Arthritis Treatment market:

An outlook of the Rheumatoid Arthritis Treatment market regional scope:

Additional takeaways from the Rheumatoid Arthritis Treatment market report:

Objectives of the Global Rheumatoid Arthritis Treatment Industry Research Report: Forecast to 2027:

Key Questions Answered in this Market Research Report:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/195609

See the rest here:
Rheumatoid Arthritis Treatment Market Summary, Trends, Sizing Analysis and Fore - News by aeresearch

Aimee Staveley has finally opened up on the heartache and courage that is hidden behind her stellar career.

The 30-year-old Leeds Rhinos forward has won just about every honour in the womens game in the past few years.

But the fact that Staveley is able to play, let along succeed at the top level, is astonishing.

She was diagnosed with psoriatic arthritis eight years ago and admits there are days the physical pain is excruciating.

The mental battles, of knowing its a crippling condition that she will always suffer with, have also taken her to some dark places.

But staggeringly Staveley believes the bad luck that fate has dealt her has helped turned her into the fierce competitor she is today.

She said: The things I have achieved in rugby are totally beyond my wildest dreams and it is amazing when I look back at what Ive done.

But I never take any of it for granted and never look too far in front or get my hopes up because I never know when Ill get an infection or a flare-up or something that will knock me back.

Staveley has decided to speak out to help other sufferers and this week completed a 100km running challenge to raise money for Versus Arthritis.

But she admits its taken her eight years to get to the point where she feels comfortable talking about it.

She said: I never wanted people to know because I didnt want to be treated any differently or to be excluded from things.

The fatigue massively affects me and is there constantly even when the pain isnt. When I have a flare up the pain is so excruciating that it feels like Ive been turned to stone.

But Ive never wanted to make excuses for myself or for others to make excuses for me.

Staveley - a treble winner with Bradford in 2017, plus Grand Final and two times Challenge Cup winner with Leeds - has previously only confided her secret with her coaches.

She said: I needed them to know if I wasnt very well or was having a flare-up and theyve all been understanding.

But by telling them it just made me try even harder to prove myself. I get very stubborn with it.

Staveley, who is furloughed from work in her career as an assistant manager for Specsavers, is also a qualified plasterer.

She said: When I went to college it was at the start of the recession so I thought Id get a trade because I knew Id then be able to work anywhere in the world.

Sign up for the brilliant new Daily Star Sport email newsletter!

From the latest transfer news to the agenda-setting stories, get it all in your email inbox.

Put your email in the box at the top of this article or you can follow instructions on this link here.

Staveley is so tough she even did this interview during a 10km run as part of her charity fund-raiser.

She said: Im a forward because of my size but I have always been very good at stamina.

I wanted to set myself something that is really hard to do so I feel proud and I thought the best charity to do it for would be the one that is close to me.

Go here to see the original:
Leeds' Aimee Staveley opens up on arthritis diagnosis that has been career inspiration - Daily Star

In this report, the COVID-19 Impact on Global Psoriatic Arthritis Therapeutics Drug market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026. COVID-19 Impact on Global Psoriatic Arthritis Therapeutics Drug market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-psoriatic-arthritis-therapeutics-drug-market-insights-forecast-to-2026

Psoriatic arthritis is a chronic autoimmune inflammatory disorder that causes inflammation, swelling, and stiffness at any joint of the body. Psoriatic arthritis is a progressive form of psoriasis, characterized by the itchy, scaly red patches on the skin.

Asia Pacific is anticipated to dominate the global market over the forecast period owing to its high demand in the region.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Psoriatic Arthritis Therapeutics Drug market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Psoriatic Arthritis Therapeutics Drug industry.

Based on our recent survey, we have several different scenarios about the Psoriatic Arthritis Therapeutics Drug YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Psoriatic Arthritis Therapeutics Drug will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Psoriatic Arthritis Therapeutics Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Psoriatic Arthritis Therapeutics Drug market in terms of both revenue and volume.

Players, stakeholders, and other participants in the global Psoriatic Arthritis Therapeutics Drug market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Sales and Pricing Analyses

Readers are provided with deeper sales analysis and pricing analysis for the global Psoriatic Arthritis Therapeutics Drug market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.

In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Psoriatic Arthritis Therapeutics Drug market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Psoriatic Arthritis Therapeutics Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Psoriatic Arthritis Therapeutics Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Psoriatic Arthritis Therapeutics Drug market.

The following manufacturers are covered in this report:

AbbVie

Janssen Biotech

Novartis

Amgen

CELGENE CORPORATION

Pfizer

Eli Lilly

UCB

Biogen

Bristol-Myers Squibb

Psoriatic Arthritis Therapeutics Drug Breakdown Data by Type

NF Inhibitors

Interleukin Inhibitors

PDE4 Inhibitors

Others

Psoriatic Arthritis Therapeutics Drug Breakdown Data by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-psoriatic-arthritis-therapeutics-drug-market-insights-forecast-to-2026

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 911 Central Avenue #268Albany New York 12206Email: [emailprotected]Phone: 1-518-730-1569Web: https://www.crystalmarketreport.com

Originally posted here:
COVID-19 Impact on Global Psoriatic Arthritis Therapeutics Drug Market Insights, Forecast to 2026 - 3rd Watch News

SynAct Pharma AB ("SynAct") today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company's lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases.

The application was filed in continuation of a preliminary European patent application the company filed in May 2019. The application includes data from a disease model of inflammatory joint diseases, the K/BxN model in mice. This arthritis model is associated with the formation of immune complexes that drive the activation of immune cells, such as neutrophils and macrophages, and the release of a number of immune mediators including cytokines and chemokines. Hence, the model mimics active stages of RA, where AP1189 currently is tested in Phase II as add-on treatment to MTX. AP1189 has previously been tested in the model (see J Immunol. 194:3381-8, 2015), and in the new dataset filed with the patent application the compound, at a sub maximal dose was given in combination with MTX. The study groups of animals were treated with either vehicle (controls), MTX, the sub-maximal dose of AP1189, or a combination with AP1189 and MTX. Treatment was started when arthritis symptoms were present, and the treatment effects were evaluated on day 7. At this timepoint, 75% of the vehicle-treated animals had developed severe disease defined as a clinical score of more than 10. In both the MTX and the AP1189 groups, 50% of the animals had developed severe disease. In the group of animals treated with the combination of AP1189 and methotrexate, no animals developed severe arthritis suggesting synergistic effects of AP1189 and MTX in RA. Further, no signs of toxicity were found in the animal treated with the AP1189 and MTX combination. The patent application will be public within 6 months from filing.

Thomas Jonassen, CSO SynAct Pharma states:

"The purpose of the patent application is to add an additional level of IP protection to our AP1189 compound. As the data generated in the animal model of RA suggest synergistic effects of AP1189 and MTX when given in combination, we have filed the claims for combination treatment of the compounds as applied in our ongoing Phase 2 study in RA. In addition to giving a broader patent protection, if granted as filed, this patent will also extend the patent runway for such combination therapy."

For further information about SynAct Pharma AB, please contact:

Jeppe vlesen Thomas Jonassen

CEO, SynAct Pharma AB CSO, SynAct Pharma AB

Phone: +45 28 44 75 67 Phone: +45 40 15 66 69Mail: joo@synactpharma.com Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.

About AP1189

SynAct Pharma's drug candidate AP1189 is a melanocortin receptor agonist on MC1 and MC3 receptors and is in clinical phase II development for the treatment of active Rheumatoid Arthritis (RA):

https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2

https://news.cision.com/synact/r/synact-pharma-files-patent-application-for-combination-of-ap1189-and-methotrexate-for-treatment-of-r,c3118819

https://mb.cision.com/Main/14427/3118819/1252860.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

See the original post:
SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases -...

TheGlobal Rheumatoid Arthritis Drugs/Therapeutics Market with (Covid-19) Impact Analysis: In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry Insights 2020 2025report has been added to Zion Market Research s offering.The Rheumatoid Arthritis Drugs/Therapeutics Market report assembles the fundamental summary of the globalRheumatoid Arthritis Drugs/Therapeutics Marketindustry. The research report represents a comprehensive presumption of the market and encloses imperative future estimations, industry-authenticated figures, and facts of the global market. It predicts inclinations and augmentation statistics with emphasis on abilities & technologies, markets & industries along with the variable market trends. It reveals fact and across-the-board consideration over the global Rheumatoid Arthritis Drugs/Therapeutics Market.

Request Free Sample Report of Rheumatoid Arthritis Drugs/Therapeutics Market Report @https://www.zionmarketresearch.com/sample/rheumatoid-arthritis-drugs-therapeutics-market

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Some of the Major Market Players Are:

Boehringer Ingelheim GmbH, AbbVie, Regeneron PharmaceuticalsInc., Novartis AG, Bristol-Myers Squibb Company, PfizerInc., UCB S.A., F. Hoffmann-La Roche Ltd., AmgenInc., and Johnson & Johnson ServicesInc.,.

The global Rheumatoid Arthritis Drugs/Therapeutics Market report highlights growth factors of the main segments and sub-segments including market growth, drivers, projections, and framework of the present conditions of the market. It presents protective and pre-planned management of the market along with embracing classification, definition, chain structure, and applications. The report uses SWOT analysis for research of the global Rheumatoid Arthritis Drugs/Therapeutics Market.

In-depth research of the Rheumatoid Arthritis Drugs/Therapeutics Market is carried out to estimate the market. It engaged the cost, utilization, rate, import, price, gross margin, production, share and supply of the market. The research analysis uses various elements of the Rheumatoid Arthritis Drugs/Therapeutics Market to evaluate the entire growth of the dominating players including their future scope. It demonstrates the positive effects standards raising revenue of the global Rheumatoid Arthritis Drugs/Therapeutics Market.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Download Free PDF Report Brochure@https://www.zionmarketresearch.com/requestbrochure/rheumatoid-arthritis-drugs-therapeutics-market

The countries like America, Japan, China, North America, the Middle East, Africa, and Europe are involved in the global Rheumatoid Arthritis Drugs/Therapeutics Market research report. The report highlights dominating players in the global market along with their highest share, growth, contact details, and sales. It displays the statistics of the global Rheumatoid Arthritis Drugs/Therapeutics Market in the form of graphical representation.

The market report estimates the significant facts and figures for the Rheumatoid Arthritis Drugs/Therapeutics Market. It offers a realistic orientation of the market that works as a useful guide for marketing, sales, analysts, executives, and consultants of the industry. It offers all the functional data in the form of tables making it convenient for the players in the market. The global Rheumatoid Arthritis Drugs/Therapeutics Market research report covers the crucial data regarding the all competitors ruling the global Rheumatoid Arthritis Drugs/Therapeutics Market.

To view TOC of this report is available upon request @https://www.zionmarketresearch.com/toc/rheumatoid-arthritis-drugs-therapeutics-market

Promising Regions & Countries Mentioned In The Rheumatoid Arthritis Drugs/Therapeutics Market Report:

The Study Objectives of Rheumatoid Arthritis Drugs/Therapeutics Market Report Are:

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/rheumatoid-arthritis-drugs-therapeutics-market

Purposes Behind Buying Rheumatoid Arthritis Drugs/Therapeutics Market Report:-

Request the coronavirus impact analysis across industries and market

Request impact analysis on this market:https://www.zionmarketresearch.com/custom/2986?covid19=true

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Original post:
Global Rheumatoid Arthritis Drugs/Therapeutics Market with (Covid-19) Impact Analysis: In-depth Analysis, Global Market Share, Top Trends,...

Global Waterproof Orthotics Market: Overview

High prevalence of diabetes, overweight, and arthritis has significantly increased the demand for waterproof orthotics. Based on the data revealed by the World Health Organization, diabetes is considered is the seventh reason behind the growing death rate across the globe. The Arthritis Foundation of the United States showed that arthritis is the main source of inability among grown-ups in the U.S. Around 47 percent of grown-ups with diabetes has joint inflammation. Thus, around 31 percent of grown-ups who are fat have joint pain. Thusly, it is significant of utilizing waterproof orthotics by the patients experienced interminable maladies which expected to develop the offers of waterproof orthotic gadgets. The results of waterproof orthotics are helpful by the people having a few sorts of medical procedure, broken bones during showering and swimming. The interest for waterproof orthotic items, for example, foot levelers, lower leg support, and sports socks are expanding step by step by the people experiencing different interminable issue, for example, diabetics, joint inflammation and heftiness.

To know Untapped Opportunities in the MarketCLICK HERE NOW

To understand these many factors, TMR Research published a fresh report on the global waterproof orthotics market. The report consists of all the major factors contributing the expansion of this market. Main focus is also on drivers, restraints, growth aspects, and lucrative opportunities that are available in the market. Thus, the report systematically provides key insights related to the growth in the global waterproof orthotics market.

Global Waterproof Orthotics Market: Notable Developments

Major players in the global waterproof orthotics market include Aetrex Worldwide, Inc., Foot Levelers, Inc., Endolite India (Chas A Blatchford & Sons), FOOTMAXX Inc., Brevard Prosthetics & Orthotics, Inc., Bio-Tech Prosthetics & Orthotics of Durham and Henderson, Turbomed Orthotics Inc., SYS Systems Ltd., 3DR Holdings, LLC, and Foot Science International.

Leading players in the global waterproof orthotics market are engaged in innovating and using advanced technologies to develop and manufacture advanced waterproof orthotics. Therefore, players are seeing investing heavily in various different business development strategies as these strategies help them in strengthening their position in the market and against their competitors.

Global Waterproof Orthotics Market: Drivers and Restraints

Because of the cutting edge way of life, a few patients experiencing different chronic diseases around the world. These days, waterproof orthotics are regularly recommending by industry experts because of its novel sterile highlights. As the waterproof orthotics are different from ordinary orthotic gadgets, the utilization of waterproof orthotics in every day existence with a lower risk to wet related diseases drives the closeout of waterproof orthotics. Nevertheless, the fit, plan, and nature of materials utilized for the waterproof orthotics are exceptionally basic so as to give elegantly satisfying and comfort to the patients in their fundamental day by day exercises.

Global Waterproof Orthotics Market: Regional Outlook

In terms of regional growth, the report on the global waterproof orthotics market covers Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Out of these regions, North America seems to hold a substantial share in the market. In this region, the U.S. is likely to be the predominant region in the waterproof orthotics market due to large presence of patients suffering with chronic diseases. Additionally, present day way of life has further increased growth opportunities in this market. Besides, growth in this market is also high in European countries as well due to growing changes taking place in the lifestyle. Other regions including India and China are also projected to contribute in the growth of this market. Significant rise in chronic diseases along with increasing modern population is the major reason behind the rise of waterproof orthotics in these countries. These changes have further opened opportunities for players as well.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Global Waterproof Orthotics Market: Overview

High prevalence of diabetes, overweight, and arthritis has significantly increased the demand for waterproof orthotics. Based on the data revealed by the World Health Organization, diabetes is considered is the seventh reason behind the growing death rate across the globe. The Arthritis Foundation of the United States showed that arthritis is the main source of inability among grown-ups in the U.S. Around 47 percent of grown-ups with diabetes has joint inflammation. Thus, around 31 percent of grown-ups who are fat have joint pain. Thusly, it is significant of utilizing waterproof orthotics by the patients experienced interminable maladies which expected to develop the offers of waterproof orthotic gadgets. The results of waterproof orthotics are helpful by the people having a few sorts of medical procedure, broken bones during showering and swimming. The interest for waterproof orthotic items, for example, foot levelers, lower leg support, and sports socks are expanding step by step by the people experiencing different interminable issue, for example, diabetics, joint inflammation and heftiness.

To know Untapped Opportunities in the MarketCLICK HERE NOW

To understand these many factors, TMR Research published a fresh report on the global waterproof orthotics market. The report consists of all the major factors contributing the expansion of this market. Main focus is also on drivers, restraints, growth aspects, and lucrative opportunities that are available in the market. Thus, the report systematically provides key insights related to the growth in the global waterproof orthotics market.

Global Waterproof Orthotics Market: Notable Developments

Major players in the global waterproof orthotics market include Aetrex Worldwide, Inc., Foot Levelers, Inc., Endolite India (Chas A Blatchford & Sons), FOOTMAXX Inc., Brevard Prosthetics & Orthotics, Inc., Bio-Tech Prosthetics & Orthotics of Durham and Henderson, Turbomed Orthotics Inc., SYS Systems Ltd., 3DR Holdings, LLC, and Foot Science International.

Leading players in the global waterproof orthotics market are engaged in innovating and using advanced technologies to develop and manufacture advanced waterproof orthotics. Therefore, players are seeing investing heavily in various different business development strategies as these strategies help them in strengthening their position in the market and against their competitors.

Global Waterproof Orthotics Market: Drivers and Restraints

Because of the cutting edge way of life, a few patients experiencing different chronic diseases around the world. These days, waterproof orthotics are regularly recommending by industry experts because of its novel sterile highlights. As the waterproof orthotics are different from ordinary orthotic gadgets, the utilization of waterproof orthotics in every day existence with a lower risk to wet related diseases drives the closeout of waterproof orthotics. Nevertheless, the fit, plan, and nature of materials utilized for the waterproof orthotics are exceptionally basic so as to give elegantly satisfying and comfort to the patients in their fundamental day by day exercises.

Global Waterproof Orthotics Market: Regional Outlook

In terms of regional growth, the report on the global waterproof orthotics market covers Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Out of these regions, North America seems to hold a substantial share in the market. In this region, the U.S. is likely to be the predominant region in the waterproof orthotics market due to large presence of patients suffering with chronic diseases. Additionally, present day way of life has further increased growth opportunities in this market. Besides, growth in this market is also high in European countries as well due to growing changes taking place in the lifestyle. Other regions including India and China are also projected to contribute in the growth of this market. Significant rise in chronic diseases along with increasing modern population is the major reason behind the rise of waterproof orthotics in these countries. These changes have further opened opportunities for players as well.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Tel: +1-415-520-1050

Here is the original post:
Waterproof Orthotics Market Real Time Analysis and Forecast 2018 2028 - 3rd Watch News

Event organizer: Maine AgrAbility and the Maine CITE Coordinating Cente

Event Date & Time: June 2, 2020 1:00 pm until June 22, 2020 2:00 pm

ORONO Maine AgrAbility and the Maine CITE Coordinating Center will host a free webinar on the prevalence of arthritis in agriculture from 12 p.m. on Tuesday, June 2.

Webinar topics include the ways arthritis can affect farmers, and how small changes in routines and using assistive technology can help reduce its impact. The webinar is free; registration is required. Information on registration and accommodation requests are on the Maine AgrAbility website.

Maine AgrAbility, a collaborative project of University of Maine Cooperative Extension and Alpha One, is dedicated to helping farmers, fishermen and forest workers work safely and more productively. For more information contact 207-944-1533 or leilani.carlson@maine.edu.

Read the original post:
Arthritis and agriculture webinar June 2 User Submitted Bangor Daily News BDN Maine - Bangor Daily News

Photographer, Basak Gurbuz DermanGetty Images

If coffee has been a constant companion during the lockdown, it might be worth looking again at your caffeine consumption. A new study suggests too many cups can be a culprit for poor health.

The research, from the University of South Australias Australian Centre for Precision Health, suggests that it all comes down to genetics: anyone with a family history of osteoarthritis, arthropathy (joint disease) or obesity may be best to sit out a few of the coffee rounds.

Using data from over 300,000 participants in the UK Biobank, researchers looked at connections between habitual coffee consumption and a full range of diseases, finding that too much coffee can increase the risk of the aforementioned conditions

In earlier research conducted by genetic epidemiologist Professor Elina Hyppnen and team, six cups of coffee a day was considered the upper limit of safe consumption.

Globally, we drink around three billion cups of coffee each day, said Professor Hyppnen, so it makes sense to explore the pros and cons of this on our health.

Typically, the effects of coffee consumption are investigated using an observational approach, where comparisons are made against non-coffee-drinkers. But this can deliver misleading results.

In this study, we used a genetic approach called MR-PheWAS analysis to establish the true effects of coffee consumption against 1,117 clinical conditions.

Coffee, of course, has also been proven to boost running performance and is a pre-race staple for many. Its worth stating that this latest research is looking at the effect of excessive coffee consumption. One or two cups a day will not damage your health; in fact, theres some evidence to suggest moderate coffee consumption could actually help you to live longer.

Reassuringly, our results suggest that, moderate coffee drinking is mostly safe, says Professor Hyppnen. But it also showed that habitual coffee consumption increased the risks of three diseases osteoarthritis, arthropathy and obesity which can cause significant pain and suffering for individuals with these conditions.

For people with a family history of osteoarthritis or arthritis, or for those who are worried about developing these conditions, these results should act as a cautionary message.

While these results are in many ways reassuring in terms of general coffee consumption, the message we should always remember is consume coffee in moderation -- that's the best bet to enjoy your coffee and good health too.

Like this article? Sign up to our newsletter to get more articles like this delivered straight to your inbox - SIGN UP

While you're at it, subscribe to the magazine here and get it through your letterbox each month - SUBSCRIBE

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Go here to see the original:
Depending on your genetics, excess coffee consumption could 'increase risk of arthritis and obesity' - Runner's World (UK)

The report on the Juvenile Idiopathic Arthritis Treatment market provides a birds eye view of the current proceeding within the Juvenile Idiopathic Arthritis Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Juvenile Idiopathic Arthritis Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Juvenile Idiopathic Arthritis Treatment market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Juvenile Idiopathic Arthritis Treatment market reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands. Juvenile Idiopathic Arthritis Treatment market reports provides all data with easily digestible information to guide every businessmans future innovation and move business forward.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2668089&source=atm

The worldwide Juvenile Idiopathic Arthritis Treatment market is an enlarging field for top market players,

The key players covered in this studyJohnson & JohnsonNovartisBristol-Myers SquibbZydus CadilaTakedaRocheLatona Life Sciences

Market segment by Type, the product can be split intoSurgical TreatmentDrug TreatmentMarket segment by Application, split intoHospitalClinicDiagnostic Laboratories

Market segment by Regions/Countries, this report coversNorth AmericaEuropeAsia-Pacific

The study objectives of this report are:To analyze global Juvenile Idiopathic Arthritis Treatment status, future forecast, growth opportunity, key market and key players.To present the Juvenile Idiopathic Arthritis Treatment development in North America, Europe and Asia-Pacific.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Juvenile Idiopathic Arthritis Treatment are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2668089&source=atm

This Juvenile Idiopathic Arthritis Treatment report begins with a basic overview of the market. The analysis highlights the opportunity and Juvenile Idiopathic Arthritis Treatment industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Juvenile Idiopathic Arthritis Treatment insight regarding the things which are driving and affecting the earnings of the market. The Juvenile Idiopathic Arthritis Treatment report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2668089&licType=S&source=atm

Research objectives and Reason to procure this report:-

Finally, the global Juvenile Idiopathic Arthritis Treatment market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Juvenile Idiopathic Arthritis Treatment industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Follow this link:
Revenues of Juvenile Idiopathic Arthritis Treatment Market Witness Severe Shocks Due to Discretionary Consumer Spending amid COVID-27 - Jewish Life...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Psoriatic Arthritis Therapeutics market.

Trusted Business Insights presents an updated and Latest Study on Psoriatic Arthritis Therapeutics Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Psoriatic Arthritis Therapeutics market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Global Psoriatic Arthritis Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global Psoriatic Arthritis Therapeutics market report has been segmented on the basis of drug, diseases type, and region.

Request Covid 19 Impact

Global Psoriatic Arthritis Therapeutics Market: Overview

Psoriatic arthritis (PsA) is a type of chronic disease, characterized by inflammation in the joints and skin. This disease is progressive category of diseases that may worsening over time. If left untreated, this psoriatic arthritis may lead to joint damage permanently. It is characterized by potential involvement of diverse tissues, including, enthesitis, peripheral and axial joints, skin & nail disease, and dactylitis. The treatment of PsA includes the use of a variety of interventions that act as an agent for the treatment of patients with other forms of inflammatory arthritis, such as rheumatoid arthritis (RA), spondyloarthritis and others.

Global Psoriatic Arthritis Therapeutics Market: Dynamics

Increasing number of cases of psoriatic arthritis especially in elderly population is a key factor expected to drive the growth of the global market over the forecast period. In addition, rising awareness about psoriatic arthritis treatment among the healthcare professionals and increasing elderly population. The above mentioned are some of the other factors expected to drive growth revenue of the global market. However, high cost of the drugs and treatment, entry of biosimilar drug in the market, and lack of standardization tools for diagnosis and treatment. These are some of the major factors expected to hamper growth of the target market to a certain extent.

Global Psoriatic Arthritis Therapeutics Market: Segment Analysis

Among the drug type segments, Nonsteroidal anti-inflammatory drug is estimated to account for majority of revenue share in the global market. This is due to, rising prescribing of NSAID drugs for patients, in order to pain and morning stiffness, controlling swelling, and to improve range of motion to joints.

Among the diseases type segments, symmetric psoriatic arthritis is estimated to hold highest revenue and register highest CAGR over the forecast period, due to increasing number of cases of affecting several joints in pairs on both sides of your body. It may damage joints over time, that can lead to limited movement and function of body.

Global Psoriatic Arthritis Therapeutics Market: Trends

The established players are adopting various growth strategies such as partnership, collaboration, mergers, new product launch etc., in order to cater the growing demand for Psoriatic Arthritis Therapeutics globally. In addition, the prominent players are collaborating with local player in order to form string value and supply chain. The aforementioned are some of the current key trend witnessed in the target market.

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

In 2019, the markets in North America estimated to account for highest market revenue share in the target market over the forecast period. This is primarily attributed to, increasing incidences of psoriatic arthritis. According to RheumatoidArthritis.org, which is a non-profit team of healthcare professionals around 85% of individuals living with psoriatic arthritis in US. The markets in Asia Pacific accounted for highest CAGR over the forecast period, owing to increasing prevalence and incidences in the temperate zones in the region, and growing healthcare expenditure. In addition, higher demand and increased rate of adoption of biologic drugs in countries such as Australia & New Zealand, are projected to drive the psoriatic arthritis therapeutics market in Asia Pacific region.

Global Psoriatic Arthritis Therapeutics Market Segmentation:

Segmentation by drug:

Nonsteroidal anti-inflammatory drug (NSAID)Disease-modifying antirheumatic drug (DMARD)Biologic drugEnzyme inhibitor

Segmentation by diseases type:

Asymmetric Psoriatic ArthritisSymmetric Psoriatic ArthritisDistal Interphalangeal Predominant (Dip) Psoriatic ArthritisSpondylitisArthritis Mutilans

Quick Read Table of Contents of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Link:
Psoriatic Arthritis Therapeutics Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Cole of Duty

Written by Manoj Dattatrye More | Pune | Updated: May 20, 2020 11:31:23 am Medical staff at Aundh Civil Hospital cheer and clap for the woman (not in the picture).

She is 65 years old and her knees ache due to arthritis. But that didnt stop her from dancing as she tested Covid-19 negative, 19 days after being admitted at Aundh Civil Hospital in Pune.A video clip of the woman, holding a stick in her hand, seen laughing and dancing has gone viral.

District Collector Naval Kishore Ram said,I have seen videos of people welcoming corona free patient back home. But this is the first time I heard a patient dancing her way out of the hospital. At least in Pune, this could be the first case. This highlights the fact that we should not fear coronavirus, but face it with confidence.

The woman, a resident of Mangalwar Peth in PMC limit, was brought to Aundh Civil Hosptial from Sassoon Hospital, apparently as the latter had run out of space to admit patients. She was in critical condition and had to be quickly put on oxygen support.

The woman is diabetic, has arthritis, was experiencing breathlessness and was unable to move without the help of a stick when admitted, doctors said. She spent at least 10 days on oxygen and in the intensive care unit of the hospital, said Dr Sharmila Gaikwad, one of the doctors who treated her.

But when the woman became free of corona status after 19 days, the joy on her face was seen to be lived. As she gingerly walked out of the hospital and staff stood by, the woman on her own started dancing.We did not stop her from having her moment. She was extremely happy She danced to express her joy after overcoming the life-threatening challenge, said Dr Gaikwad.

While leaving for home, the woman thanked the doctors and the nurses and told them that she survived because of them. I thought I would die but you people saved my life. I will never forget you all, the woman told the medical staff as they cheered and clapped.

Sister Priyanka Jadhav, among those took care of the patient, said,The woman was very worried initially, she was repeatedly asking whether she will get well or notShe used to be bed-ridden for days, we helped her eat food and drink water.

Dr Gaikwad said since the woman is diabetic, her sugar levels were fluctuating. Since her sugar levels were fluctuating, she was also facing breathing problem. We had to stabilise her condition with medicine. She was given a combination low molecular weight heparin and HCQ tablets, a treatment method which was working on serious patients, doctors said.

The doctors also conducted physiotherapy sessions. The patient has arthritis and her knees used to ache. We gave physiotherapy which helped the pain to ease, Dr Gaikwad said.

When the elderly woman patient was shifted out of the ICU to the positive patients ward, she quickly endeared herself to other patients. The young patients in the ward used to extend all kind of help to her. They used to give her water and take her to the bathroom. She became popular with the younger lot, said Dr Gaikwad.

The patient was also very inquisitive. She used to repeatedly ask her why she was put on saline, why blood was being drawn from her, when is her negative report going to come ?, Dr Gaikwad said.

The doctors at Aundh Civil Hospital said if a patient remains confident and determined, it helps in their early recovery. What we have experienced is that if a patient has determination to overcome the ailment, he does so. This is because if you harbour fear or negative thoughts, your body does not respond. Almost all the positive patients are a worried lot. It is only through counselling that they stablise after initially being gripped by extreme fear, said Medical officer Dr Prakash Rokde.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Pune News, download Indian Express App.

The Indian Express (P) Ltd

Read more:
Elderly woman with arthritis breaks into a dance after beating Covid-19 at Pune hospital - The Indian Express

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive preliminary results from the Companys second interim analysis of its ongoing NAV3-31 Phase 2B study. Analysis demonstrates that these interim data further corroborate Navideas hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis (RA), and that this imaging can provide an early indicator of treatment efficacy in patients with active RA.

Navideas NAV3-31 Phase 2B trial titled Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc99m Tilmanocept Planar Imaging has three arms: Arm 1 consists of healthy subjects, Arm 2 is comprised of patients with active, moderate-to-severe RA who are on stable therapy, and Arm 3 is a pilot arm of the upcoming Phase 3 trial assessing the ability of Tc99m tilmanocept to provide an early indicator of efficacy of anti-tumor necrosis factor (TNF) alpha treatment in RA patients.

This second interim analysis was designed to examine data from Arm 3 of the study in order to evaluate the magnitude of change of Tc99m tilmanocept signal localized to RA-involved joints in patients before and after treatment with an anti-TNF alpha therapy as well as to examine whether this change in localization, if any, can serve as an early, quantifiable predictor of treatment efficacy.

A total of 15 subjects with active moderate-to-severe RA were included in this interim analysis, each of which was set to begin a new or first-time treatment regimen with an anti-TNF alpha therapy. Whole body and hand/wrist planar gamma camera images were obtained at baseline prior to initiation of new treatment, again at 5 weeks post therapy initiation, and then again at 12 weeks on 8 of the 15 subjects. The remaining 7 subjects had received baseline and 5-week scans only at the time of this analysis. A panel of established clinical assessments was performed at each time point as well, in order to compare imaging results with clinical standards over the 12-week time course. Results of the preliminary analysis demonstrate:

These interim data are supportive of Navideas hypotheses that Tc99m tilmanocept imaging can provide quantifiable imaging assessment of RA-involved joints that enables early prediction of clinical response as well as longitudinal monitoring of clinical status.

Michael Rosol, Chief Medical Officer for Navidea, said, We are encouraged by these interim results, which are in line with our hypotheses, support the continuation of the current Phase 2B study, and will be fundamental to speaking with the FDA about moving forward into the Phase 3 trial later this year. Dr. Rosol continued, We are excited that we are on track to possibly providing rheumatologists and those suffering with RA a noninvasive, quantifiable, early indicator of whether or not an anti-TNF alpha treatment is working. This could bring enormous benefit to these patients by assisting physicians in putting them on the right course of treatment earlier than would otherwise be possible today.

Jed Latkin, Navideas Chief Executive Officer, said, I am once again very pleased that the interim results of our ongoing Phase 2B study are so encouraging. These data support our belief that Tc99m tilmanocept imaging has the potential to provide an early and accurate indication of treatment effectiveness to rheumatologists, allowing them to tailor effective treatment regimens for RA patients. We are looking forward to continuing our progress into a Phase 3 study.

RA is a chronic disease affecting over 1.3 million Americans and as much as 1% of the worldwide population1. If the product is successfully developed, Navidea would expect to play a major role in the management of RA patients worldwide.

Conference Call Details

Investors and the public are invited to dial into the conference call through the information listed below, or participate via the audio webcast on the company website, http://www.navidea.com. Participants who would like to ask questions during the question and answer session will be prompted by the moderator, who will provide instructions.

Reference1. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navideas Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navideas strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Companys pipeline through global partnering and commercialization efforts. For more information, please visit http://www.navidea.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding our current studies and potential results, FDA approval process, ability to provide rheumatologists and those suffering from RA with expected benefits, the accuracy and timing of our imaging as an indication of treatment effectiveness, the use of our imaging as part of treatment for RA patients, our ability to progress into a Phase 3 study, our ability to successfully develop products, and the role of Navidea in the management of RA worldwide. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.

Investors are urged to consider statements that include the words will, may, could, should, plan, continue, designed, goal, forecast, future, believe, intend, expect, anticipate, estimate, project, and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Navidea is not responsible for the contents of third party websites.

Continued here:
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis - Business Wire

Dive Brief:

Filgotinib has become a defining drug for Galapagos. It's what attracted Gilead when the companies began working together in 2015 a partnership that since sprouted into a $5 billion research deal. It's also key to validating Galapagos' drugmaking capabilities.

Filgotinib had previously shown its merit in rheumatoid arthritis, as late-stage studies found it reduced joint swelling without eliciting some of the safety concerns which have weighed on its drug class, known as JAK inhibitors. Gilead, which holds U.S. rights to the drug, submitted it for approval as a rheumatoid arthritis treatment at the end of last year.

Galapagos, though, believes filgotinib can work across a wide range of immune conditions, including Crohn's disease, uveitis and psoriatic arthritis. Many studies testing the drug in these indications have paused enrollment due to the coronavirus pandemic. Fortunately for Galapagos, the Phase 2b/3 study in ulcerative colitis had already fully enrolled.

The results released Wednesday show the placebo-adjusted clinical remission rate was about 11% for biologic-naive patients on the 200 mg regimen of filgotinib and about 7% for patients who had before taken some kind of biologic. While these were significantly better than the placebo group, the lower, 100 mg dose didn't fare as well by week 10.

The incidence of serious adverse events, meanwhile, was similar across all three groups. Importantly, rates of venous thrombosis and pulmonary embolism, which are two of the safety issues that have loomed over JAK drugs, were "low and comparable across treatment groups in both the induction and maintenance phases of the study," according to the companies.

While hard to compare because of differences in design, patient enrollment and the definition of "clinical remission," the new efficacy data for filgotinib appear roughly on-par with what other JAK inhibitors have shown in ulcerative colitis.

Xeljanz, which was approved for the disease in 2018, showed placebo-adjusted efficacy of 10% to 14% in biologic-naive patients and 8% to 12% in biologic-experienced patients, according to RBC Capital Markets analyst Brian Abrahams. AbbVie's Rinvoq, which was recently cleared for rheumatoid arthritis, had placebo-adjusted remission rates of 6% to 11% in biologic-experienced patients

As such, filgotinib was "not a standout winner, but not a loser either" following its latest ulcerative colitis data, according to Abrahams. RBC models around $4 billion in peak sales for filgotinib across all its potential indications. Investment bank Stifel, meanwhile, predicts that filgotinib at its peak could fetch $4 billion from ulcerative colitis alone.

Others, however, took a more critical view.

Analysts at Credit Suisse covering Arena Pharmaceuticals wrote that the filgotinib data were "largely underperforming efficacy expectations" for the JAK inhibitor class in ulcerative colitis. Arena, notably, is developing a rival ulcerative colitis medicine called etrasimod that works in a different way than JAKs to reduce inflammation.

Galapagos shares were down more than 7% Thursday morning, while Gilead's were relatively unmoved.

Continue reading here:
High expectations cast a shadow over Gilead and Galapagos' positive data - BioPharma Dive

Looking back into history, gout, or gouge as it is sometimes called, was once thought to be the rich mans curse for their enslavement of the lower classes who did all the work for the rich men who did not enjoy the fruits of their labors.

As the rich became older and richer a fair portion of them were plagued with rapid onset of searing and swollen red large toes which was described as being so painful that even having a thin bed sheet placed on it was unbearable.

Hippocrates used to utilize the colchicum plant to help treat this painful condition, but this approach grew out of favor within the medical profession by the 1700s when it became more appropriate to bleed the victim as a treatment.

Modern medicine can help to shed a light on what was happening back in those early days; the wealthy having enough money to lounge around and dine on rich meat filled diets that were washed down with copious amounts of wine were lacking nutrition in their diets that the poor workers were getting as they ate their garden vegetables and primarily drank water, which is for the most part what is now recognized as the source of whether or not one develops gout or not.

The body recycles old and dying cells as it harvests the building blocks to make new cells, but the process declines with age. These building blocks are called purines, if they are produced in excess or not excreted through the kidneys efficiently they form needle shaped uric acid crystals. An autoimmune attack is triggered that causes impressive amounts of inflammation of the joints when the immune system detects these crystals accumulating on a joint.

Over time this process can cause destruction similar to the appearance of rheumatoid arthritis. One of the more common causes of this overproduction is alcohol intake and diets that are rich in purines such as those found in steak and lobster, which the rich back in the day had in excess in their diets while the poor workers had very low levels of in their diets.

Sometimes the body does not excrete uric acid efficiently, this is most often caused by medications such as diuretics used to treat high blood pressure. Additionally there are some genetic lines such as Polynesians who can lack enzymes that break down uric acid in purines to be used to make new cells, and in these cases the uric acid often causes gout.

One of the other myths surrounding gout is that a blood test for uric acid can either diagnose or disprove this form of arthritis; but research shows that most patients suffering with gout attacks will have normal blood uric acid levels, and most with elevated levels do not go on to develop gout though for this group the risk of developing kidney stones is elevated.

Advances in modern medical science allows for the detection of gout crystals to be seen in joints with painless musculoskeletal ultrasounds, but in the past the only way to check for the presence of gout versus other forms of arthritis was rather painful and involved sticking a needle into the joint to draw out fluids for microscopic investigation.

In todays modern society there are many effective forms of treatment for gout, and it is now commonly thought of as the only curable form of arthritis. One of the quickest acting medications used to treat gout is colchicine, which interestingly enough was originally used by Hippocrates back in the day; history really does repeat itself in some cases.

Arthritis is a complicated condition, as such gout can happen along with other forms of arthritis simultaneously, and this can be confusing for the patient and physician alike. Fortunately there are many forms of diagnostics and treatment options available that make treating gout easier.

If a weight loss program is recommended to help treat gout, be sure to select the program carefully as some popular low carb fad diets also have a high fat content which can promote hyperuricemia by stimulating fat burning for energy producing a state of ketosis; the problem with this diet is that it can make the gout condition worse, especially in the initial phases of diet change and weight loss. The gout condition can also get worse with simple fasting or crash diets that can raise uric acid levels. Be sure to have a discussion with your physician or certified medical profession to work out a plan that works best for you to avoid any possibility of unwanted complications.

View post:
Gout: Possibly The Only Curable Form Of Arthritis - Anti Aging News

Arthritis is no walk in the park. In fact, it can make any walk around the park inconvenient, painful and arduous. And, did you know that one form of arthritis can even lead to lung damage?

Rheumatoid arthritis is an autoimmune disease whereby the immune system mistakenly attacks the lining of the joints.

Specifically, the synovium the tissue lining around the joint that produces a fluid to help the joint move freely is targeted.

This causes joint inflammation and pain, mainly experienced in the hands, knees and ankles.

Some people with rheumatoid arthritis may experience fatigue and have a low-grade fever.

The symptoms of this condition come and go, with a flare-up lasting anywhere from a couple of days to months.

Aside from joint pain, the most common health complication that develops from rheumatoid arthritis is problems with the lungs.

This includes small growths in the lungs, called pulmonary nodules.

DON'T MISS

And a build-up of fluid between the lung and chest wall, known as pleural effusion.

Or damage to the airways, known as bronchiectasis. It can even lead to interstitial lung disease (ILD).

In fact, it's estimated that one in 10 people with rheumatoid arthritis will develop ILD.

ILD refers to inflammation and scarring of the lung tissue caused by an overactive immune system.

Read the original:
Rheumatoid arthritis: How the autoimmune disease can lead to lung disease - Express

Study data published in Clinical Rheumatology support the discriminatory capacity of the European League Against Rheumatism (EULAR) definition of arthralgias suspicious for progression to rheumatoid arthritis (RA). In a cohort of patients with hand arthralgias, the EULAR criteria, combined with ultrasound and laboratory data, correctly classified 92% of cases with RA.

Investigators conducted a prospective cohort study of adults older than 18 years with hand arthralgias between August 2017 and July 2019. At baseline, patients underwent an ultrasound (US) with power Doppler (PD) of both hands and radiography of the hands and feet. Laboratory tests were used to determine erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, rheumatoid factor (RF) positivity, and anti-cyclic citrullinated peptide antibodies (ACPA) positivity. Patients were followed by their treating rheumatologists; the primary outcome was diagnosis of RA per 2010 EULAR criteria. The area under the receiving operator curve (AUC) was used to evaluate the diagnostic performance of EULAR criteria for arthralgias likely to progress to RA. Multivariate logistic regression analyses were performed to identify baseline predictors of RA development. The EULAR definition for suspicious arthralgias includes 7 features; EULAR risk was expressed as the number of features observed in each patient.

The study cohort comprised 465 patients with hand arthralgias, among whom 358 (76.9%) were women. Mean age at baseline was 53.814.5 years. During follow-up, 44 patients (9.4%) were diagnosed with RA by their treating rheumatologists. Mean baseline number of EULAR features was 4.11.6 in patients who were later diagnosed with RA vs 2.31.5 in patients without RA (P <.0001). RF, ACPA, and the presence of synovitis by US with PD were more commonly observed in the RA vs the non-RA group.

The AUC for EULAR features for final diagnosis of RA was 0.7827 (95% CI, 0.7150-0.8503), indicating modest discrimination. When US with PD, RF, and ACPA data were added to EULAR features, the AUC increased to 0.9172 (95% CI, 0.8794-0.9550; P <.001). In the final model, the best cutoff for number of EULAR-defined features was 4, which had a sensitivity of 90.9% and a specificity of 76.5%.

In multivariate regression, baseline features associated with later diagnosis of RA included difficulty making a fist (odds ratio [OR], 60.3; 95% CI, 3.6-1004), RF positivity (OR, 111.7; 95% CI, 9.9-1252), ACPA positivity (OR, 220.8; 95% CI, 12.3-3956), and US with PD in at least 1 joint (OR, 117.4; 95% CI, 8.8-1553).

The EULAR definition of arthralgia suspicious for progression to RA performed well in distinguishing patients who were later diagnosed with RA from patients who were not. The addition of other laboratory features to the EULAR prediction model increased discrimination. Overall, EULAR features appear to be useful for identifying RA risk in patients with hand arthralgias.

Reference

Ruta S, Prado ES, Chichande JT, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. Clin Rheumatol. 2020;39:1493-1499.

View original post here:
EULAR Criteria Predicts Progression to Rheumatoid Arthritis in Patients With Hand Arthralgias - Rheumatology Advisor

PSORIATIC ARTHRITIS (PSA) is a chronic inflammatory disease characterized by joint pain, stiffness, and swelling and clinically presents as axial or peripheral arthritis, dactylitis, and nail or skin lesions. Usually PsA occurs after the development of psoriasis. However, in a small number of patients, joint problems begin before psoriasis appears.1

More than 8 million Americans live with psoriasis, and PsA affects between 15% and 30% of those individuals.2 The disease also affects men and women almost equally, with a peak onset age between 40 and 50 years, although it can begin at any time.1,3 A hereditary link also appears evident, as individuals who have a first-degree relative with the condition have a 40% greater chance of developing the disease.4

Effective and timely treatment is important in PsA because the earlier it is diagnosed, the sooner treatment can begin, thus slowing down permanent joint and tissue damage and the progression of disability.1 However, diagnosis is often delayed because of the generality of symptoms, and study results show that just 30% of patients receive a proper diagnosis within the first 6 months of symptom onset.5,6

Although the number of drugs for PsA has increased over the past decade, half of treated patients still do not achieve optimal outcomes, and little guidance exists to help practitioners with medication choice. Physicians make their decisions based on the clinical disease domain affected, cost, and provider familiarity.7

Considerations and Goals of Therapy No cure for PsA exists, so the goals of treatment are to slow disease progression, improve quality of life, lessen pain, and preserve range of motion. With variable presentation and 5 subtypes of disease, practitioners must assess the clinical presentations and locations affected and choose therapy accordingly.6,7

Therapeutic treatment is usually focused on a particular goal, with minimal disease activity (MDA) criteria recommended as the treatment target in patients with PsA. Evidence shows that patients who meet those criteria have better quality of life, less joint damage, and more functional ability.7 Practitioners also need to consider comorbidities because patients suffering from PsA are more likely to have cardiovascular disease, metabolic syndrome, depression, and diabetes.1,4

Treatment Selection and Strategies In most patients with PsA, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs if a patient does not adequately respond.1,2 However, the American College of Rheumatology (ACR) and the National Psoriasis Foundation have challenged this historical approach, instead recommending biological DMARDs as first-line therapy.2,3,7,8

Biological therapy has 5 mechanisms, with tumor necrosis factor (TNF) inhibitors the most established. Patients often receive these as first-line therapy because of more robust outcome data, physician familiarity, and lower costs due to TNF biosimilars. Interleukin (IL-17A, IL-12, and IL-23) inhibitors tar get disease-specific cytokines. Oral small molecules include Janus kinase inhibitors that block the downstream signal of multiple cytokine receptors and a PDE4 inhibitor that blocks the degradation of cyclic adenosine monophosphate in immune cells, thus inhibiting an inflammatory response.7,9

A preferred hierarchy of drug selection has not been established, and because of the clinical heterogeneity of PsA, large studies need to evaluate the different clinical domains of the diseases. To date, only 1 large head-to-head study has compared biologics for PsA. In that study, Mease et al compared the IL-7 inhibitor ixekizumab with adalimumab, and results showed the superiority of ixekizumab in the primary outcome of patients achieving ACR50 criteria and 100% reduction in the Psoriasis Area and Severity Index.10 The study results also showed noninferiority to adalimumab.10

Physicians have no way to predict who will and will not respond to therapies, and because biological and targeted synthetic DMARD treatment usually lasts for 12 to 24 weeks, a longer period of suboptimal therapy may result.2,3 These delays can also contribute to both negative outcomes and decreased quality of life.

Future DirectionThe approach of using biologics in patients with PsA without an evidence-based stratification or personalization tool has led to more than 50% of patients not meeting their therapeutic target as defined by the MDA criteria. Some patients who have failed prior first-line biological therapy may have a response when they switch to a drug with a different mechanism of action, which may suggest that disease pathogenesis can differ among individuals.7,11

In 2019, the first study addressing precision medicine in PsA was published. Miyagawa and colleagues conducted the trial and looked at evaluating baseline CD4 T-cell activation markers to select appropriate therapy for patients with PsA.12 Even though the trial had limitations, the results were promising, and it was the first study to use baseline immunophenotyping when selecting therapy.7,12

Personalized treatment selection has had success in other autoimmune disease states, such as rheumatoid arthritis. In the future, a combination of immunophenotyping and statistical analyses could assist in a targeted treatment approach that has the potential to maximize outcomes in patients with PsA without delay.7

What Pharmacists Should Know Many effective DMARDs are available. However, patients respond differently and may not achieve optimal outcomes with their first choice of treatment, which contributes to delays and poorer long-term results. Practitioners should base treatment selection on clinical areas involved, comorbidities, and evidence. Many biologics also have specialty distribution pathways, which can present a challenge to patients who must navigate the system.

Although new treatment selections offer opportunities for therapy, they also present new challenges, and pharmacists must be knowledgeable about evidence-based studies that can help guide and individualize treatment for PsA.

REFERENCES

Go here to see the original:
What Is the Future of Psoriatic Arthritis Treatment? - Pharmacy Times

Depression and anxiety were highly prevalent in patients with rheumatoid arthritis (RA), according to study results published in the International Journal of Rheumatic Diseases. The study findings also highlighted that better self-reported global health status was protective against both anxiety and depression symptoms.

Investigators conducted a prospective, cross-sectional study of patients enrolled in either the Siriraj Rheumatoid Arthritis Registry (SIRA) or the Thai Army Rheumatoid Arthritis Cohort (TARAC) between September 2016 and March 2018. Established at major hospitals in Bangkok, Thailand, the SIRA and TARAC cohorts comprised patients aged 18 years with a diagnosis of RA per the American College of Rheumatology criteria. At baseline, SIRA and TARAC enrollees provided sociodemographic and clinical information; patients were then followed-up prospectively through rheumatology clinic visits. The present analysis extracted depression and anxiety data from most recent visit, assessed using the Thai version of the Hospital Anxiety and Depression Scale (HADS). Anxiety and depression were defined as having a HADS score 8. Logistic regression was conducted to identify baseline factors associated with HADS score at follow-up.

Data from 464 patients were included in analysis. Mean age at most recent study visit was 5911.4 years, median disease duration was 9.9 years (interquartile range, 5.1-16.6 years), and 85% were women. Nearly half (48%) of participants were unemployed. Mean HADS score for depression was 3.833.11; mean score for anxiety was 4.712.95. The overall prevalence rates for depression and anxiety were estimated at 12.5% and 14.5%, respectively. Increased disease activity was observed in patients with anxiety and depression, although this trend was not statistically significant.

In multivariate regression models, global health score (risk ratio [RR], 0.98; 95% CI, 0.96-0.99; P =.001) was negatively associated with depression. Anxiety was positively associated with the presence of functional disability (RR, 2.46; 95% CI, 1.33-4.54; P =.004) and being married (RR, 2.43; 95% CI, 1.25-4.73; P =.009), but negatively associated with disease duration 10 years or more (RR, 0.45; 95% CI, 0.25-0.80; P =.007) and global health score (RR, 0.97; 95% CI, 0.95-0.98; P <.001). Overall, patients who self-reported better global health were less likely to endorse depression and anxiety.

These data underscore the significant burden of mood disorders in patients with RA. As a study limitation, investigators noted that the cross-sectional design prevented longitudinal analysis of mood symptoms, which may fluctuate over time with changing disease activity. Even so, given these results, mental health screenings may be an important component to clinical care for RA.

Reference

Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P, Srisomnuek A. Prevalence of and factors associated with depression and anxiety in patients with rheumatoid arthritis: a multicenter prospective cross-sectional study. Int J Rheum Dis. 2020;23(3):302-308.

Continue reading here:
Depression, Anxiety Highly Prevalent in Patients With Rheumatoid Arthritis - Rheumatology Advisor